Eli Lilly and : Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial
INDIANAPOLIS, May 22, 2021 /PRNewswire/ -- In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company's mirikizumab improved fatigue in patients with moderately to severely... | May 22, 2021